Showing results (1-10 of 241) with videos related to
Sort By:
Pageof 25
Statistical Methods in Medical Research|September 20, 2018
A Bayesian adaptive phase II clinical trial design accounting for spatial variationBeibei Guo, Yong ZangStatistics in Medicine|August 28, 2020
BILITE: A Bayesian randomized phase II design for immunotherapy by jointly modeling the longitudinal immune response and time-to-event efficacyBeibei Guo, Yong ZangStatistical Methods in Medical Research|February 22, 2022
A Bayesian phase I/II biomarker-based design for identifying subgroup-specific optimal dose for immunotherapyBeibei Guo, Yong ZangStatistics in Medicine|November 25, 2021
BIPSE: A biomarker-based phase I/II design for immunotherapy trials with progression-free survival endpointBeibei Guo, Yong ZangStatistical Methods in Medical Research|November 29, 2015
Optimal two-stage enrichment design correcting for biomarker misclassificationYong Zang, Beibei GuoPharmaceutical Statistics|September 26, 2022
A Bayesian phase I/II design to determine subgroup-specific optimal dose for immunotherapy sequentially combined with radiotherapyBeibei Guo, Yong Zang, Li-Hsiang Lin, et al.Statistical Methods in Medical Research|March 15, 2023
Bayesian order constrained adaptive design for phase II clinical trials evaluating subgroup-specific treatment effectMu Shan, Beibei Guo, Hao Liu, et al.Pharmaceutical Statistics|March 25, 2022
SCI: A Bayesian adaptive phase I/II dose-finding design accounting for semi-competing risks outcomes for immunotherapy trialsYifei Zhang, Beibei Guo, Sha Cao, et al.Statistics in Medicine|April 11, 2019
A Bayesian adaptive marker-stratified design for molecularly targeted agents with customized hierarchical modelingYong Zang, Beibei Guo, Yan Han, et al.Clinical Trials (London, England)|January 11, 2024
Adaptive phase I-II clinical trial designs identifying optimal biological doses for targeted agents and immunotherapiesYong Zang, Beibei Guo, Yingjie Qiu, et al.Pageof 25